No, you're not dreaming: the Venus Optics Laowa 12mm f/2.8 FF II C&D Dreamer is coming next week
Lens-maker Venus Optics has officially announced that it will be releasing a new 12mm f/2.8 full-frame autofocus lens on June 25, 2025. The Laowa 12mm f/2.8 FF II C&D Dreamer will be available in Sony E and Nikon Z mounts with full autofocus, and there will also be Canon RF and L-mount Alliance versions, although these will be manual-focus only.
While Venus Optics has garnered a stellar reputation for producing innovative and often unusual manual focus lenses with remarkably low distortion, this new lens is only the second from the brand to have autofocus, joining the recently released Laowa 10mm f/2.8 FF II C&D Dreamer, which again offers autofocus in its Nikon and Sony versions, with other mounts only having manual focus.
According to Venus Optics, the 'C&D Dreamer' designation in its Laowa lens range is broken down as follows. The 'C' signifies a compact build, the 'D' means minimum distortion, and the 'Dreamer' bit is reserved for lenses that exhibit soft, artistic image rendering.
Indeed, it is compact and light, weighing around 377 grams, depending on the lens mount, and has a reasonably svelte 72mm filter thread. And Venus Optics claims that it produces images with a near-zero distortion. We'll see if our tests bear this out when we get our hands on a review sample.
It's not the first 12mm f/2.8 Laowa lens – that honor goes to the Laowa 12mm f/2.8 Zero-D, which was released back in 2016. But while this 'Zero-D' model signifies a 'close-to-zero distortion' design, it is a significantly heftier lens, weighing in at around 609 grams, and is only available in manual focus, whatever the mount.
While pricing details are expected to be officially released at the time of the announcement on June 25, I expect the lens will be competitively priced. As a rough guide, the autofocus versions of the Laowa 10mm f/2.8 lens cost £799 / £849 / AU$1,449.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Ceconomy enters talks with China's JD.com for potential takeover
German electronics retailer Ceconomy, which operates MediaMarkt and Saturn brands, is engaged in advanced talks with Chinese e-commerce company over a possible voluntary public takeover. is contemplating a cash offer of €4.60 per ordinary share, compliant with the German Securities Acquisition and Takeover Act, according to Ceconomy's statement of 24 July 2025. No binding agreements have yet been reached, and it remains uncertain whether a formal takeover offer will proceed. The Chinese company disclosed its interest in a potential deal towards the end of 2023. Reuters reports that a proposed transaction could value the company at approximately €2.2bn ($2.59bn). Ceconomy's largest shareholder is the Kellerhals family, while the Haniel family owns 17%. Meridian, Beisheim and Freenet hold smaller stakes. 36.3% of Ceconomy's shares are freely traded. MediaMarkt and Saturn manage 1,030 stores across multiple European countries and employ 50,000 staff, as of 30 September 2024. The brands also operate a major online electronics retail platform. In the 2023/24 financial year, Ceconomy recorded total sales of €22.4bn, of which €5.1bn were online. According to Bloomberg, logistics division's delivery network could enhance the operations of Ceconomy's physical retail outlets. In the first quarter of 2025, reported net revenues of $41.5bn and net income attributable to the company's ordinary shareholders of $1.5bn. The Chinese company launched an export-to-domestic sales programme in April, 2025, with plans 'to procure no less than 200bn yuan worth of export-oriented goods for domestic sales'. In August 2024, Walmart sold its stake in to raise $3.74bn, a term sheet seen by Reuters has revealed. The decision was part of the US retailer's strategy to focus on its own operations within China. Walmart sold 144.5 million American depositary shares priced between $24.85 and $25.85. "Ceconomy enters talks with China's for potential takeover" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Cheetah Mobile to Acquire Controlling Stake in UFACTORY to Accelerate Its Robotics Commercialization Strategy
BEIJING, July 28, 2025 /PRNewswire/ -- Cheetah Mobile Inc. (NYSE: CMCM) ("Cheetah Mobile" or the "Company"), a China-based IT company, today announced that one of its majority-owned subsidiaries has signed a definitive agreement to acquire an equity interest of 60.8% in Shenzhen UFACTORY Technology Co., Ltd. ("UFACTORY"), a leading provider of lightweight robotic arms, for a total consideration of approximately RMB99.5 million. Prior to the transaction, another wholly-owned subsidiary of Cheetah Mobile already held 19.2% of UFACTORY's total equity interest. Following the transaction, the two subsidiaries will collectively hold approximately 80.0% of UFACTORY's total equity interest, representing Cheetah Mobile's ultimate beneficial ownership in UFACTORY of approximately 75.8%. The transaction has been approved by the Company's board of directors and audit committee and is expected to close in the third quarter of 2025, subject to customary closing conditions. Mr. Sheng Fu, Cheetah Mobile's Chairman and Chief Executive Officer, commented, "We're excited to deepen our investment in UFACTORY, a fast-growing leader in collaborative robotics. With its robust technology stack and lean go-to-market approach, UFACTORY is an ideal partner to support our next stage of growth in AI and robotics. With this acquisition, we're strengthening our product portfolio to help our service robots operate across more physical environments and tasks. This marks a significant step forward in our mission to deliver smarter, more adaptable robotics solutions to global markets." Mr. Thomas Ren, Cheetah Mobile's Director and Chief Financial Officer, commented: "We will fund the acquisition with our cash reserves. As of March 31, 2025, we held over USD230 million in net cash, giving us ample flexibility to pursue strategic investments that have the potential to deliver sustainable shareholder value." About UFACTORY UFACTORY is a leading provider of lightweight collaborative robotic arms - designed to safely work alongside humans in shared environments. Under the brand "UFACTORY xArm", the company is one of the few robotic arm providers generating net profits and substantial revenue from overseas markets, having achieved sustained growth over the past years. Backed by proprietary full-stack robotics technologies, UFACTORY offers a diverse portfolio of five-, six-, and seven-axis robotic arms and robotic accessories. UFACTORY's developer-friendly design makes its robotic arms and accessories highly adaptable across different use cases, empowering customers with flexibility and ease of deployment. UFACTORY has built a loyal, global customer base with increasing revenues from international markets. About Cheetah Mobile Inc. Cheetah Mobile is a China-based IT company with a commitment to AI innovation. It has attracted hundreds of millions of users through an array of internet products and services on PCs and mobile devices. At the same time, it actively engages in the independent research and development of AI technologies, including LLM technologies. Cheetah Mobile provides advertising services to advertisers worldwide, value-added services including the sale of premium membership to its users, multi-cloud management platform to companies globally, as well as service robots to international clients. Cheetah Mobile is also committed to leveraging its cutting-edge AI technologies, including LLM technologies, to empower its products and make the world smarter. It has been listed on the New York Stock Exchange since May 2014. Safe Harbor Statement This press release contains forward-looking statements. These statements, including management quotes and business outlook, constitute forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in the forward-looking statements, including but are not limited to the following: Cheetah Mobile's growth strategies; Cheetah Mobile's ability to retain and increase its user base and expand its product and service offerings; Cheetah Mobile's ability to monetize its platform; Cheetah Mobile's future business development, financial condition and results of operations; competition with companies in a number of industries including internet companies that provide online marketing services and internet value-added services; expected changes in Cheetah Mobile's revenues and certain cost or expense items; and general economic and business condition globally and in China. Further information regarding these and other risks is included in Cheetah Mobile's filings with the U.S. Securities and Exchange Commission. Cheetah Mobile does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. Investor Relations Contact Helen Jing ZhuCheetah Mobile +86 10 6292 7779Email: ir@ View original content: SOURCE Cheetah Mobile Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
5 minutes ago
- Yahoo
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic areas, including respiratory, immunology and inflammation, and oncology. The collaboration is poised to enhance Hengrui's globalisation strategy and provide GSK with significant growth opportunities beyond 2031. GSK will pay an upfront fee of $500m, which includes licensing for the phosphodiesterase (PDE)3/4 programme. The potential value of future success-based payments to Hengrui Pharma could be close to $12bn, assuming all programmes are optioned and milestones met. Hengrui Pharma is also set to receive tiered royalties on worldwide product net sales, with certain regional exclusions. A highlight of the agreement is the worldwide licence for HRS-9821, a PDE3/4 inhibitor in clinical development for chronic obstructive pulmonary disease (COPD). HRS-9821 aligns with GSK's goal to address a broad spectrum of COPD patients, including those with ongoing dyspnoea or those less likely to be prescribed inhaled corticosteroids or biologics. In early trials, this inhibitor showed positive anti-inflammatory and bronchodilation effects. Its potential for a dry-powder inhaler formulation could integrate well with GSK's existing inhaled portfolio. Hengrui Pharma executive vice-president and chief strategy officer Frank Jiang stated: 'GSK brings additional research and development expertise, a robust global clinical network and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programmes to overseas markets, potentially delivering breakthrough treatments to patients globally." Beyond HRS-9821, the collaboration includes up to 11 additional programmes. Hengrui Pharma will spearhead the development up to Phase I trials, after which GSK may opt to develop further and commercialise the programmes globally, excluding mainland China, the Macau special administrative region (SAR), Hong Kong SAR and Taiwan. This scaled collaboration is designed to expedite the development of innovative medicines, leveraging GSK's expertise and global reach alongside Hengrui Pharma's discovery and clinical evaluation capabilities. The licensing of HRS-9821 is contingent upon customary regulatory clearances, including under the Hart-Scott-Rodino Act in the US. In March 2025, MSD entered an exclusive licence agreement with Hengrui Pharma for the investigational oral small-molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. "Hengrui Pharma and GSK link across key therapeutic areas" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
